

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

July 3, 2024

To Shareholders,

Company Name: Renaissance Inc.

Representative: Keisuke Furuta, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

**Notice of Revision of Full-Year Earnings Forecasts for the Fiscal Year Ending March , 2025**

The Company resolved by a written resolution instead of a resolution of its Board of Directors, to revise its full-year earnings forecasts for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), which were announced on May 9, 2024, as follows.

Particulars

1. Revisions to the forecast of financial results for the current fiscal year (April 1, 2024 to March 31, 2025)

	Operating revenue	Operating profit	Ordinary income	Net income for the year	Net income for the year (Per share)
Previous forecast (A)	Millions of yen 90	Millions of yen △275	Millions of yen △275	Millions of yen △108	Yen Sen △8.53
Revised forecast (B)	105	△257	△257	△91	△7.18
Increase (Decrease) (B-A)	15	17	17	17	
Increase (Decrease) (%)	17.4	—	—	—	
(Reference) Results for the previous period (Fiscal year ended March, 2024)	194	△252	△251	△258	△20.32

2. Reason for revision

The Company has revised its financial results due to the expected receipt of a milestone payment of US\$100,000 from Eirion Therapeutics, Inc.